These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35898359)

  • 1. A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection.
    Raza S; Osasan S; Sethia S; Batool T; Bambhroliya Z; Sandrugu J; Lowe M; Okunlola O; Hamid P
    Cureus; 2022 Jun; 14(6):e26313. PubMed ID: 35898359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review.
    Sarker A; Ramesh AS; Munoz C; Jamil D; Tran HH; Mansoor M; Butt SR; Satnarine T; Ratna P; Hamid P
    Cureus; 2022 Sep; 14(9):e29069. PubMed ID: 36249645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
    Rabizadeh S; Nakhjavani M; Esteghamati A
    Int J Endocrinol Metab; 2019 Apr; 17(2):e84353. PubMed ID: 31372172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
    Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
    Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
    Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
    Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.
    Herat LY; Magno AL; Rudnicka C; Hricova J; Carnagarin R; Ward NC; Arcambal A; Kiuchi MG; Head GA; Schlaich MP; Matthews VB
    JACC Basic Transl Sci; 2020 Feb; 5(2):169-179. PubMed ID: 32140623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
    Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.